NCT00865761View on ClinicalTrials.gov

A Relative Bioavailability Study of Alprazolam 3 mg ER Tablets Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

September 30, 2005

Study Completion Date

September 30, 2005

Conditions
Healthy
Interventions
DRUG

Alprazolam 3 mg Extended Release Tablets, single dose

A: Experimental Subjects received Alpharma formulated products under fasting conditions

DRUG

XANAX XR® 3 mg tablets, single dose

B: Active comparator Subjects received Pharmacia \& Upjohn Company formulated products under fasting conditions

Trial Locations (1)

58102

PRACS Institute, Ltd., Fargo

Sponsors

Lead Sponsor

Actavis Inc.
All Listed Sponsors
lead

Actavis Inc.

INDUSTRY

NCT00865761 - A Relative Bioavailability Study of Alprazolam 3 mg ER Tablets Under Fasting Conditions | Biotech Hunter | Biotech Hunter